Welcome to Psychiatryai.com: Latest Evidence - RAISR4D

Estimated reading time for CME/CPD: 1 min

From metabolic dysfunction to neurodegeneration: mechanisms and hierarchical candidate biomarkers in diabetes-associated cognitive impairment

AI Summary
  • Metabolic dysfunction including hyperglycaemia, AGE-RAGE signalling, insulin resistance and dyslipidaemia drives oxidative stress, mitochondrial dysfunction and neuroinflammation causing neuronal injury.
  • Neurons, microglia and astrocytes mediate pathology: impaired neuronal energy, synaptic plasticity, neurogenesis; microglial activation and astrocytic lipid changes exacerbate cognitive decline.
  • Biomarker landscape: few clinically validated markers; distinguishes clinical, genetic and mechanistic candidates but requires systematic validation in well characterised human DACI cohorts.
Summarise with AI (MRCPsych/FRANZCP)

Exp Neurol. 2026 Nov 4:116103. doi: 10.1016/j.expneurol.2026.116103. Online ahead of print.

ABSTRACT

Diabetes-associated cognitive impairment (DACI) is a common complication of diabetes that severely affects patients’ quality of life. However, biomarkers for its clinical diagnosis and treatment remain limited. DACI pathogenesis involves hyperglycemia, advanced glycation end products (AGE)-receptor for AGE interactions, insulin resistance, and lipid metabolism disorders, which induce oxidative stress, mitochondrial dysfunction, and neuroinflammation. Neurons, microglia, and astrocytes are key cellular mediators. Metabolic disorders directly impair neuronal energy metabolism, synaptic plasticity, and neurogenesis, while microglial activation and functional reprogramming, astrocytic lipid synthesis, and synaptic remodeling further promote neuronal dysfunction and cognitive decline. This review distinguishes clinically investigated biomarkers from genetic susceptibility factors, emerging mechanistic candidates, evaluates them by evidence level and potential clinical roles in risk assessment, diagnosis, disease monitoring, treatment-response assessment, and therapeutic targeting. Integrating mechanistic and biomarker evidence provides a framework for future research, early diagnosis, and targeted therapeutic development. However, many candidate biomarkers have been investigated primarily in preclinical models or related diseases such as Alzheimer’s disease and require systematic validation in well-characterized human DACI cohorts.

PMID:42982395 | DOI:10.1016/j.expneurol.2026.116103

Document this CPD

Share Evidence Blueprint

QR Code

Save to Google Notes

Search Google Scholar

⭐ My Revision List

close chatgpt icon
ChatGPT

Enter your request.

← →
RAISR4D CME/CPD Evidence Nodes
Swipe to navigate RAISR4D CME/CPD evidence nodes.
CME/CPD